Lu-Ann Murdoch
ARTICLES BY THIS AUTHOR
- 3/4/2024
Two therapeutic options now available for treating severe alopecia areata in Canada
The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet. - 2/29/2024
Study examines the safety of COVID-19 XBB.1.5 vaccines in older adults
Denmark study finds no increased risk of 28 adverse events following vaccination with a monovalent XBB.1.5-containing vaccine given as a fifth dose to adults 65 years or older. - 2/27/2024
Bariatric surgery superior to other interventions in type 2 diabetes
Bariatric surgery leads to better glycemic control, less diabetes medication use and higher rates of diabetes remission compared with medical/lifestyle intervention. - 2/24/2024
Optimizing medications and reducing polypharmacy through medication reviews
The European iSIMPATHY project proves the value of a seven steps approach to medication reviews, enabling pharmacists to manage polypharmacy. - 2/22/2024
Drug news—February
A review of new launches, new indications, new dosage forms and Health Canada advisories. - 2/22/2024
Effect of testosterone on progression from prediabetes to diabetes in hypogonadal men
New study examines the efficacy of testosterone gel in preventing progression from prediabetes to diabetes, and in inducing glycemic remission in men with diabetes. - 2/21/2024
Myfembree now available for use in women with endometriosis, uterine fibroids
This new combo product will be used to manage heavy menstrual bleeding associated with uterine fibroids, and moderate to severe pain associated with endometriosis. - 2/20/2024
Two new women’s health products are now available by prescription in Canada
Knight Therapeutics launches Imvexxy (estradiol vaginal inserts) for postmenopausal dyspareunia and Bijuva (estradiol/progesterone capsules) for menopausal vasomotor symptoms. - 2/8/2024
Study shows significant risk of major drug-drug interactions in outpatient children
One in five U.S. Medicaid-insured children are exposed to major drug interactions annually, with higher risk in those with multiple medical or mental health conditions.
